AstraZeneca's Phase 3 Trial for Lung Cancer Drug Succeeds, and Sandoz Secures $322 Million Biosimilar Deal
Tagrisso and Orpathys Combination Therapy Achieves Positive Results in Phase 3 (SAFFRON) Trial, Pioneering Targeted Lung Cancer Treatment
AstraZeneca (AZN) and HUTCHMED (HCM), jointly developing the epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treatment Tagrisso (osimertinib) in combination with the MET inhibitor Orpathys (savolitinib), have achieved positive results in the Phase 3 (SAFFRON) trial, demonstrating improved survival rates. The combination therapy showed significant improvements in progression-free survival (PFS) and overall survival (OS) in patients with MET amplification mutations who had previously received Tagrisso as a first- or second-line treatment. Compared to the existing standard treatment, platinum-based doublet chemotherapy, the combination therapy demonstrated superior survival benefits, marking a new milestone in overcoming resistant lung cancer. Based on the SAFFRON results, the companies plan to promptly submit approval applications to global regulatory agencies, including the U.S. Food and Drug Administration (FDA).
Sandoz Enters into a $322 Million Strategic Biosimilar Deal with Shanghai Henlius
Sandoz (SDZ), a Swiss generic pharmaceutical company, has strengthened its global pipeline by entering into a licensing agreement with Shanghai Henlius Biotech (2696.HK) for up to $322 million. Through this agreement, Sandoz will acquire exclusive commercialization rights outside of China for three biosimilars developed by Henlius, including Erbitux (cetuximab) from Eli Lilly, Repatha (evolocumab) from Amgen, and Benlysta (belimumab) from GSK. Additionally, Sandoz has secured an option to introduce a recombinant human hyaluronidase (HLXTE-HAase1001) technology that conveniently converts intravenous (IV) formulations into subcutaneous (SC) formulations. Sandoz plans to pay approximately $150 million in upfront payments and near-term milestones for the initial assets in 2026, aiming to penetrate the original drug market, which has an annual combined value of approximately $10.8 billion.
MapLight Therapeutics Pursues Partnership for Autism Treatment After Phase 2 (IRIS) Trial Failure
MapLight Therapeutics (MPLT), a U.S.-based biopharmaceutical company specializing in neurological disorders, has begun seeking strategic partnerships for its autism spectrum disorder (ASD) treatment candidate, ML-004. ML-004, a selective 5-HT1B/1D receptor agonist, recently completed a Phase 2 (IRIS study) trial, which failed to meet the primary endpoint of improving social communication deficits, necessitating a modification of the development strategy. However, the drug demonstrated significant improvements in the Aberrant Behavior Checklist-Irritability (ABC-I) score in a subgroup of adolescents (12-17 years) with moderate-to-severe irritability, preserving some potential for commercialization. As a result, MapLight plans to hold an End-of-Phase 2 meeting with the U.S. FDA to coordinate the development direction for targeting adolescent irritability and to secure a licensing agreement or a joint research partner to diversify the development risk.
BMS and Celgene Shareholders' $6 Billion CVR Legal Dispute Re-Ignited with Appellate Court's Remand
The $6 billion contingent value right (CVR) lawsuit between Bristol Myers Squibb (BMY) and Celgene shareholders has been sent back to trial following a ruling by the Federal Appellate Court. The Second Circuit Court of Appeals overturned the district court's decision, which had dismissed the lawsuit, finding that UMB Bank, the trustee for the Celgene shareholders, had standing. The shareholders allege that BMS intentionally delayed the FDA approval of the CAR-T therapy Breyanzi (lisocabtagene maraleucel) to avoid paying the $6 billion CVR promised during the 2019 Celgene acquisition. This remand decision exposes BMS to billions of dollars in potential liabilities and long-term legal risks, impacting its financial and legal standing.
AstraZeneca's successful Phase 3 trial of the Tagrisso and Orpathys combination therapy represents a significant advancement in the $12 billion to $16 billion global EGFR-targeted therapy market, offering a new standard of care that will compete with Janssen's Libtayo and Retevmo combination therapy. Sandoz's $322 million deal with Shanghai Henlius is a strategic move to secure a foothold in the market for three major assets (Erbitux, Repatha, and Benlysta), which have combined original drug sales of approximately $10.8 billion, and to differentiate its products through the introduction of a technology that converts IV formulations into SC formulations. MapLight Therapeutics' failure to meet the primary endpoint in the Phase 2 trial of ML-004 highlights the challenges in developing new drugs for autism treatment, but the drug's safety profile and efficacy in a subgroup of adolescent patients with irritability suggest that it may still have potential for future licensing or partnership opportunities. Finally, the appellate court's remand of the $6 billion CVR lawsuit between BMS and Celgene shareholders underscores the importance of corporate governance and the financial risks associated with failing to meet the terms of contingent value rights agreements in mergers and acquisitions.
Source: BioPharma Dive (rss)
https://www.biopharmadive.com/news/astrazeneca-sandoz-china-bristol-myers-maplight/828058/